Immunotherapy in preneoplastic disease: Targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance

Bridget Keenan, Elizabeth M. Jaffee

Research output: Contribution to journalArticle

Abstract

Recent advances in immunotherapy have demonstrated that single agent vaccines can be effective when given as primary prevention before exposure to the causative agent, and partially effective in some patients with existing cancer. However, as tumors develop and progress, tumor-induced immune suppression and tolerance present the greatest barrier to therapeutic success. Preneoplastic disease represents an important opportunity to intervene with tumor antigen-targeted vaccines before these mechanisms of immune evasion outpace efforts by the immune system to destroy precancerous cells. However, as we discuss in this review, emerging evidence suggests that procarcinogenic inflammatory changes occur early in cancer development, in both patients and mouse models of cancer progression. Defining early inhibitory signals within tumor microenvironments will yield insights that can eventually be used in the clinic to target these events and deliver treatments that can be used in addition to cancer vaccines to prevent premalignant and early invasive cancers.

Original languageEnglish (US)
Pages (from-to)12-16
Number of pages5
JournalAnnals of the New York Academy of Sciences
Volume1284
Issue number1
DOIs
StatePublished - May 2013

Keywords

  • Cancer vaccines
  • Immunotherapy
  • Pancreatic cancer
  • Preneoplasia

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Fingerprint Dive into the research topics of 'Immunotherapy in preneoplastic disease: Targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance'. Together they form a unique fingerprint.

  • Cite this